serum institute of india

Different strains of human papillomavirus (HPV) cause most cervical cancers. The Department of Biotechnology (DBT) and Serum Institute of India (SII) is launching our country's first quadrivalent human papillomavirus vaccine (HPV). The…

India's first indigenously developed quadrivalent human papillomavirus vaccine (qHPV) for the prevention of cervical cancer will be launched in the next few months and will be affordable to all, minister of state for science and…

Subject expert committee (SEC) of the drug regulator has reviewed and approved phase-3 infants clinical trial data of Biological E's paediatric vaccine against streptococcus pneumonia and recommended its manufacture, the Hyderabad-based…

Vaccine maker Biological E (BE) on Thursday said that the Subject Expert Committee of the Central Drugs Standard Control Organisation(CDSCO) has reviewed and approved the phase-3 infants clinical trial data and recommended for…

NEW DELHI: India is all set to launch on Thursday its first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for prevention of cervical cancer. It has been developed by the Serum Institute of India(SII) in…

The Serum Institute of India (SII) and the Department of Biotechnology(DBT) are set to launch India's first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against Cervical Cancer on September 1, official sources…

The Indian vaccine makers including Serum Institute of India (SII), Biological E and Bharat Biotech are gaining a wider share in the overall vaccine market and are growing month-on-month. According to a TOI report,…

A slow but discernible change is visible in the usually staid vaccine market. Indian companies including Serum Institute of India (SII), Biological E and Bharat Biotechare cornering a wider share, growing month on month in an otherwise…

US biotechnology major Novavax on Wednesday said two large phase-3 trials of its COVID-19 vaccine being manufactured by Pune-based Serum Institute of India have shown that the jab provides high levels of protection against mild,…

MUMBAI: Pune-based Serum Institute of Indiais working on an Omicron-specific vaccine for Covid-19 with its US partner, Novavax. The vaccine is expected to be rolled out within six months. The vaccine will be specific to the BA5…